Buyer’s checklist
A buyer’s checklist for AI clinical tools in senior care
Evaluate an AI clinical tool the way you would evaluate a clinical protocol, not the way you would evaluate software. Require written answers to 35 questions across 6 groups — clinical boundary, validation evidence, workflow and alert burden, data and integration, governance and accountability, and contractual terms — and treat any refusal to answer in writing as an answer.
Two questions separate serious vendors from confident ones: what is the alert burden per nurse per shift, and who is accountable when a signal fires and nothing happens. Ask them of SeniorCRE too; our answers are on this page.
- Questions
- 35 across 6 groups
- Format
- Require written vendor answers, not demonstrations
- Hardest questions
- Alert burden per shift and named accountability
- Last reviewed
- October 22, 2026
Author and clinical review
Written by the SeniorCRE Clinical Intelligence Group. Clinically reviewed by the SeniorCRE Clinical Review Panel.
Registered-nurse clinical operations review (director-of-nursing and chief-nursing-officer practice background in skilled nursing and assisted living), paired with a regulatory-compliance reviewer and a data-governance owner. Every clinical page in this cluster requires all three sign-offs before publication.
SeniorCRE publishes the review structure rather than an individual byline: the dedicated Clinical Safety Officer seat is open and under active recruitment, and no individual clinician is named as a public sponsor of this content until that seat is filled and the person consents to attribution. Nothing on these pages is medical advice, and none of it establishes a clinician–patient relationship.
Reviewed at publication and re-reviewed at least quarterly, or on any change to cited guidance. Last reviewed October 22, 2026. The Clinical Safety Officer role is open.
Scope and evidence posture. SeniorCRE clinical intelligence is decision support: it surfaces deterioration signals and reconciles them with staffing, documentation, and operating context so a licensed clinician can act sooner. It does not diagnose, does not assign a clinical severity score of record, and does not initiate treatment or transfer. Capabilities described here are built; there is no published operator-production outcome data, and SeniorCRE makes no claim about mortality, transfers, length of stay, survey results, or cost avoided.
Capability · Validated · Production
Capability
Does it exist in the product?
Built
The signal framework, the acknowledgment and escalation ladder, dismiss-with-reason, provenance capture, and the per-signal-class kill switch are implemented in the platform.
Validated
Has it been exercised, and against what?
Built; not validated
Exercised against synthetic resident fixtures and vendor-documented interface contracts, with clinical review of wording, ranking, and dismissal flow. No external clinical validation study has been published, and no performance figure is claimed.
Production
Is it running on real residents today?
Not in operator production
There is no completed operator-production clinical deployment and no operator-production outcome data. Live clinical exposure is gated on an executed BAA, a named clinical owner, the operator’s own written change-in-condition protocol, a silent-run period, and written DON acceptance.
The checklist
Six groups. Ask them of every vendor on your list, including SeniorCRE, and require written answers rather than demonstration confidence.
A. Intended use and clinical boundary
If a vendor cannot answer this group in writing, stop here.
- Is there a written intended-use statement naming what the tool does, what it explicitly does not do, and the populations it was not built for?
- Does the output constitute decision support, or does it assert a diagnosis, triage level, or severity score of record?
- Can a clinician independently review the basis for every recommendation, or is the output unexplainable at the point of care?
- Is the tool positioned as a regulated medical device, and if not, on what basis is that determination made?
- Who is contractually accountable when a signal is wrong — and does the contract disclaim all clinical responsibility?
B. Evidence
Vendor-reported performance is a hypothesis, not evidence.
- Is there external validation by someone other than the vendor, in a peer-reviewed or publicly auditable form?
- Was validation performed in a setting comparable to yours — assisted living or skilled nursing, not an academic ICU?
- Are sensitivity, specificity, positive predictive value, and alert burden reported together, with the prevalence assumed?
- What is the reported lead time, measured from what event, against what comparison standard of care?
- Are the denominators, exclusions, and study period stated, and can a reference site confirm them?
- Will the vendor run a silent validation on your own historical data before any clinician sees an alert?
C. Safety workflow
The workflow around the model matters more than the model.
- Is human review mandatory at every action point, and is that guaranteed by design rather than by configuration?
- What is the acknowledgment window, and what is the escalation ladder if nobody acknowledges?
- Can clinicians dismiss with a reason, and are dismissal reasons reviewed to retire noisy signals?
- Is there an agreed alert-burden budget per nurse per shift, and what happens contractually if it is exceeded?
- Is there a kill switch your clinical leadership can pull immediately, per signal and per community, without vendor approval?
- Can residents on comfort-focused or hospice care be excluded by data field rather than by staff memory?
- Does the tool ever write orders, medications, or transfer decisions autonomously?
D. Bias, drift, and monitoring
A model that was fine at go-live is not necessarily fine in month nine.
- Are firing rates and dismissal rates monitored across resident cohorts and communities, and who reviews the comparison?
- What triggers a model or threshold retrain, and who must approve it before it reaches clinicians?
- How are you notified when the model version changes, and can you refuse a version?
- Is performance monitored continuously against your own data, or only at implementation?
- What is the process when a missed signal or near-miss is reported, and what is the response commitment?
E. Data, privacy, and rights
Ownership questions get harder after signature, never easier.
- Is a BAA executed before any PHI moves, and are the data categories in scope enumerated?
- Can your data be used to train models that benefit other customers, and can you refuse that without losing the product?
- Is there an LLM or third-party AI subprocessor in the path, and is there a BAA with that subprocessor?
- Can you export your full data set, including signals, acknowledgments, and audit logs, in a usable format at any time?
- What is the audit-log retention period, and is the log append-only?
- What happens to your data at termination, on what timeline, and with what certificate of deletion?
F. Implementation and contract
Most clinical AI failures are integration and adoption failures.
- What structured data does the tool require, at what capture frequency, and does your documentation actually meet it today?
- Does the tool reproduce your own change-in-condition protocol, or impose the vendor’s clinical criteria?
- How does resident identity reconcile across EHR, eMAR, dietary, incident, and staffing systems, and what is the match rate?
- Who trains staff, how long is the silent-run period, and what is the written acceptance gate before clinical exposure?
- Is the tool integrated into your existing QAPI cadence, or does it live in a separate dashboard nobody opens?
- Is pricing tied to claimed outcomes you cannot audit, and is there an exit if the alert burden proves unworkable?
Decision support versus diagnosis: the line, stated plainly
SeniorCRE clinical intelligence is decision support. It surfaces a change from a resident’s own baseline, shows the observations behind it, and routes it to a licensed clinician with a clock on it. It does not name a condition, does not assign a severity score of record, does not order tests, does not change medications, and does not initiate a transfer. The clinical record of truth remains the operator’s EHR and eMAR.
| Dimension | Decision support (SeniorCRE) | Diagnosis (clinician only) |
|---|---|---|
| What is produced | A ranked deterioration signal with the specific observations that raised it, timestamped and attributable. | A named condition assigned to a resident as a clinical finding of record. |
| Who decides | A licensed clinician reviews the signal, examines the resident, and records the assessment and disposition. | A licensed clinician, exclusively — no software may occupy this role. |
| What the software may do on its own | Surface, rank, route, remind, document, and escalate on a timer if unacknowledged. | Nothing. SeniorCRE issues no diagnosis, orders no test, changes no medication, and initiates no transfer. |
| Reversibility | Every signal can be dismissed with a reason; the dismissal is retained and monitored for pattern. | Amended only through the clinical record by the responsible clinician. |
| Record of truth | The operating record holds the signal, the acknowledgment, the action, and the timing. | In a parallel configuration the incumbent EHR or eMAR keeps medication administration and SeniorCRE reads one direction only, so exactly one medication record stays authoritative. Where an operator elects it, SeniorCRE’s own EHR and eMAR carry the clinical record. |
| Failure mode if ignored | An unacknowledged signal escalates by role and time, and the gap is visible in governance reporting. | Out of scope by design — the system never holds a diagnosis that could be silently missed. |
Workflow safeguards
Ten safeguards govern every clinical signal. They are properties of the design, not operator configuration options, and none of them can be disabled to make a demonstration look faster.
Safeguard 1
Human-in-the-loop is mandatory, not configurable
Every signal terminates at a named licensed clinician. There is no auto-action path, no auto-escalation to a physician without a nurse acknowledgment, and no operator setting that removes the human step.
Safeguard 2
Signal, not score of record
Output is presented as "these observations changed" with the contributing evidence shown, not as a clinical severity score that could be mistaken for a validated instrument such as NEWS2, qSOFA, or SOFA.
Safeguard 3
Timed acknowledgment with role escalation
Unacknowledged signals escalate on a clock — charge nurse, then director of nursing, then the on-call clinical leader — and the elapsed time is retained for governance review.
Safeguard 4
Dismiss-with-reason is required
A clinician can always dismiss a signal, but must record why. Dismissal reasons are reviewed in aggregate to detect nuisance patterns and to retire signals that waste clinical attention.
Safeguard 5
Alert-burden budget
Thresholds are tuned to a stated alerts-per-nurse-per-shift budget agreed with the operator before go-live. Exceeding the budget is treated as a defect, because alarm fatigue is a patient-safety hazard, not a tuning preference.
Safeguard 6
Silent-run period before clinicians see anything
Signals run in shadow against the operator’s own historical and live data first. Clinical exposure begins only after the clinical review panel and the operator’s DON accept the observed signal volume and character.
Safeguard 7
No autonomous change to orders, medications, or transfer status
SeniorCRE writes no order, no medication change, and no transfer decision. Integrations that write back to a clinical system are scoped, logged, and clinician-initiated.
Safeguard 8
Full provenance on every signal
Each signal carries its input observations, their source systems, capture times, model or rule version, and the identity of everyone who saw and acted on it. The trail is append-only.
Safeguard 9
Documented kill switch
The operator’s clinical leadership can disable any signal class immediately, per community or portfolio-wide, without a support ticket and without vendor approval.
Safeguard 10
Equity and drift monitoring
Signal firing rates and dismissal rates are monitored across resident cohorts and across communities. Divergence triggers review before it becomes a care-quality difference.
Limitations, stated before you ask
The most useful thing a vendor can publish about clinical AI is where it stops working.
- Prediction is not diagnosis. A signal states that a pattern consistent with clinical deterioration has appeared; only a clinician can determine whether infection or sepsis is present.
- Externally validated performance of widely deployed proprietary sepsis prediction models has been substantially lower than vendor-reported performance in the peer-reviewed literature, and any operator should demand external validation rather than internal marketing figures — including from SeniorCRE.
- Most published sepsis-prediction evidence comes from acute-care inpatient settings with continuous monitoring and frequent labs. Assisted living and skilled nursing have sparser vitals, fewer labs, and different baselines, so acute-care performance does not transfer.
- Signal quality is bounded by observation frequency. A community that documents vitals once per shift cannot support the same sensitivity as one with more frequent structured observation, and the honest answer is a narrower signal set rather than a confident score.
- Atypical presentation in older adults cuts both ways: baseline-relative signals catch presentations that absolute thresholds miss, but they also raise more signals in residents with unstable baselines, dementia, or end-of-life trajectories.
- Residents on comfort-focused or hospice care require an explicit exclusion pathway; escalating deterioration signals against a documented goals-of-care decision is a harm, not a save.
- False alarms have a real clinical cost. Alarm fatigue degrades response to true signals, which is why alert burden is budgeted and monitored rather than treated as a tuning afterthought.
- SeniorCRE publishes no sensitivity, specificity, lead-time, transfer-avoidance, mortality, or cost figure of its own. There is no completed operator-production clinical pilot as of October 22, 2026, and any number without a named site, period, denominator, and comparison should be treated as marketing.
Governance model
Governance follows the structure the CDC set out for hospital sepsis programs: named leadership, defined action, tracking, reporting, and education. The controls below are what an operator can audit.
| Control | Who owns it | Evidence an operator can audit |
|---|---|---|
| Intended-use statement per signal class | SeniorCRE clinical review panel | A written intended-use, out-of-scope, and known-limitations statement shipped with each signal class. |
| Change control on signals and thresholds | Clinical review panel plus operator DON | Versioned signal definitions; no threshold change reaches clinicians without operator sign-off. |
| Human-factors review of the clinician surface | Clinical review panel | Reviewed wording, ranking, and dismissal flow so a signal cannot read as a diagnosis. |
| Alert-burden monitoring | Operator DON with SeniorCRE | Alerts per nurse per shift tracked against the agreed budget; overage opens a defect. |
| Equity and drift review | Data governance owner | Firing and dismissal rates compared across cohorts and communities on a fixed cadence. |
| Audit trail | Platform | Append-only logs with UTC millisecond timestamps, full user and session context, and long-horizon retention. |
| Operator data rights | Contract | Operator owns its data, can export it in full, and controls whether its data is used for any model work. |
| Incident and near-miss reporting | Operator clinical leadership with SeniorCRE | A defined path for reporting a missed or misleading signal, with a written response commitment. |
Clinical and regulatory sources
These sources describe the clinical problem, the consensus definitions, the published limits of sepsis prediction models, and the transparency expectations for decision-support software. None of them reports SeniorCRE performance, and none should be read as doing so.
Source 1 · Singer et al., JAMA · 2016
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Defines sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, and introduces qSOFA (altered mentation, systolic BP ≤100 mmHg, respiratory rate ≥22/min).
Source 2 · Evans et al., Critical Care Medicine / Intensive Care Medicine · 2021
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
Recommends against qSOFA as a single screening tool and supports systematic screening of acutely ill, high-risk patients — the basis for treating any signal as screening support rather than a decision.
Source 3 · U.S. Centers for Disease Control and Prevention · 2023
Hospital Sepsis Program Core Elements
Establishes leadership accountability, action, tracking, reporting, and education as the structural elements of a sepsis program — the model our governance section follows.
Source 4 · Wong et al., JAMA Internal Medicine · 2021
Independent validation found substantially poorer discrimination than the vendor reported, with a high alert burden. Cited here as the reason to demand external validation from any vendor — including SeniorCRE.
Source 5 · Royal College of Physicians · 2017
National Early Warning Score (NEWS2)
The reference standardized deterioration score. SeniorCRE does not reproduce or substitute for NEWS2; signals are explicitly labelled as not a validated severity score.
Source 6 · U.S. Food and Drug Administration · 2022
Clinical Decision Support Software — Guidance for Industry and FDA Staff
Describes the criteria that separate non-device clinical decision support from regulated device software, including whether the clinician can independently review the basis for the recommendation.
Source 7 · U.S. Assistant Secretary for Technology Policy / ONC · 2024
HTI-1 Final Rule: Decision Support Interventions and Predictive DSI transparency (source attributes)
Sets the transparency expectations — intended use, inputs, validation, fairness, and maintenance — that the buyer’s checklist on this site mirrors question for question.
Source 8 · U.S. Centers for Disease Control and Prevention · 2024
Sepsis: Clinical Information and Data
Background on sepsis burden and the role of early recognition. Used for problem framing only; no SeniorCRE outcome is derived from it.
Frequently asked questions
What should you ask a vendor before buying an AI clinical tool?
Ask for written answers across six areas: the clinical boundary (does it diagnose or prompt), validation evidence (population, setting, and whether performance was measured outside the development site), workflow and alert burden (alerts per nurse per shift and the kill switch), data and integration (which systems, what latency, whose data), governance (who owns thresholds and how changes are logged), and contract terms (indemnity, audit rights, exit and data return). Our published checklist contains 35 specific questions.
What is a reasonable alert burden?
The right number is one your clinical leadership agrees to in advance and can sustain, expressed per nurse per shift and monitored after go-live. What matters is less the specific number than whether the vendor will commit to a budget, measure against it, and reduce sensitivity if the budget is exceeded. A vendor unwilling to name a budget is transferring alert-fatigue risk to your nurses.
How do you tell decision support from a diagnostic claim?
Read the output language. Decision support prompts an assessment and shows the observations behind the prompt. A diagnostic claim names a condition, asserts a severity, or implies an action. If marketing says "detects sepsis" while the product says "assess this resident," the marketing is the problem and the contract should reflect the product.
What validation evidence should you require?
Ask for the population and setting the model was developed in, whether performance was evaluated in a setting other than the development site, how documentation and vitals cadence affect performance, and what happens when inputs are missing. Published sepsis-prediction evaluations show performance degrades when transferred across populations and documentation patterns, so development-site metrics alone are not evidence for your building.
What are SeniorCRE’s own answers to this checklist?
SeniorCRE clinical intelligence is decision support only, reproduces the operator’s own screening criteria rather than authoring clinical criteria, publishes no clinical outcome or dollar-value claim, and as of October 22, 2026 is built; not validated rather than operator production with no completed operator-production deployment to cite. Alert-burden budgets, named signal ownership, and documented kill switches are non-optional parts of the design.
Should the checklist be part of the contract?
Yes, where it can be. Alert-burden budgets, threshold-change notification, audit rights over signal logs, data return on exit, and the explicit statement that the tool is decision support and not a diagnostic device belong in the agreement rather than in a slide.
Continue in this cluster
Is SeniorCRE your clinical system of record? Capability vs. configuration
The platform carries its own EHR and eMAR and can be the clinical system of record — or it can run alongside an existing eMAR, reading one direction only, so one medication record stays authoritative. Both configurations, side by side.
Answers: Is this replacing my eMAR?
How AI supports earlier sepsis detection in senior residents
A clinician-reviewed guide to the signals, the escalation workflow, the published limits of sepsis prediction models, and the safeguards that keep detection support out of diagnosis.
Answers: How does AI support earlier sepsis detection in older adults in senior housing & care?
Clinical and financial intelligence in assisted living
How acuity, care minutes, staffing, documentation, census, and revenue are reconciled with operator-controlled authority — and where the clinical record still governs.
Answers: What is clinical and financial intelligence in assisted living, and how are the two reconciled?
Human review and escalation: who acknowledges, who decides, who is accountable
The acknowledgment clock, the role-by-role escalation ladder, dismiss-with-reason, the kill switch, and what the record retains about every human step.
Answers: Who reviews an AI clinical alert, and what happens if nobody does?
Data sources and limitations behind clinical signals
Every input class, the system it comes from, its capture reliability, and the specific limitation it imposes on any signal built from it.
Answers: What data does clinical AI use in senior housing & care, and where does it stop working?
QAPI and survey-readiness use cases
Six governed QAPI and survey-readiness use cases, each with the question it answers, the evidence it produces, and the limit on what it can claim.
Answers: How is clinical intelligence used for QAPI and survey readiness?
- Pillar: Clinical intelligence for senior housing & care
- Product: Clinical platform · Clinical workflows
- Vendor comparison: Clinical and financial analytics platforms for assisted living
- Security and compliance posture: Trust Center
Evaluate this the way you would evaluate a clinical protocol
The honest version of this conversation is a readiness review against your own documentation, vitals cadence, and change-in-condition protocol — followed by a silent run on your own data before any clinician sees a signal.